ClinicalTrials.gg
CompletedNCT01804842Updated Oct 21, 2016Results posted

Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM

A Phase 1/2 interventional study of Met DR in Type 2 Diabetes Mellitus, sponsored by Elcelyx Therapeutics, Inc.. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-10-21.

Sponsored by Elcelyx Therapeutics, Inc. · Phase 1/2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
236th of 287
26 · median 100
Started
2012
with 22 others
Phase 1/2
3 of 293
none open now
Registered
172nd of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 236th largest by enrollment of the 287 interventional ones that give a count, is one of 23 that started in 2012, is one of 3 in phase 1/2, and was the 172nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compared the effects of delayed-release metformin (Met DR, EFB0027) administered once daily in the morning (qAM), administered once daily in the evening (qPM), and administered twice daily (BID) on circulating glucose concentrations and metformin pharmacokinetics (PK) in subjects with type 2 diabetes mellitus (T2DM).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 70 (inclusive) years old at Visit 1 (Screening)
  2. Was diagnosed with type 2 diabetes mellitus with

    • between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with:

      i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at Visit 1) of DPP-4 inhibitor alone OR

    • HbA1c between 6.0 to 8.5% (inclusive) for subjects managing their diabetes with a stable (minimum of 2 months at Visit 1) combination regimen of metformin and DPP-4 inhibitors
  3. Had normal renal function with an estimated (eGFR) ≥90 mL/min/1.73 m\^2 based on the Modification of Diet in Renal Disease (MDRD) equation
  4. (BMI) of 25.0 to 40.0 kg/m\^2 (inclusive) at Screening
  5. Male, or if female and met all of the following criteria:

    • Not breastfeeding
    • Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at Visit 1 (Screening) (not applicable to hysterectomized females)
    • Surgically sterile, , or if of , practiced and was willing to continue to practice appropriate during the entire duration of the study
  6. Had a physical examination with no abnormalities as judged by the investigator
  7. Ability to understand and willingness to adhere to protocol requirements
  8. If on chronic thyroid pharmacologic therapy, the dose must have been stable for at least 3 months prior to Visit 1 (Screening), and must have thyroid-stimulating hormone (TSH) test result in normal range at Visit 1 (Screening)

Exclusion criteria

Exclusion Criteria:

  1. Had a medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:

    • Hepatic disease
    • Renal disease
    • Gastrointestinal disease
    • Endocrine disorder except diabetes
    • Cardiovascular disease
    • Central nervous system diseases
    • Psychiatric or neurological disorders
    • Organ transplantation
    • Chronic or acute infection
    • Orthostatic hypotension, fainting spells or blackouts
    • Allergy or
  2. Had any chronic disease requiring medication that was adjusted in the past 90 days (subjects could take acute intermittent over-the-counter medications such as Tylenol, if needed)
  3. Had any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening)
  4. Had major surgery of any kind within 6 months of Visit 1 (Screening)
  5. Had received a blood transfusion within 6 months of Visit 1 (Screening)
  6. Had a history of >5 kg weight change within 3 months of Visit 1 (Screening)
  7. Had clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities other than those expected in subjects with type 2 diabetes and judged by the investigator to be clinically significant at Visit 1 (Screening)
  8. Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study
  9. Abused drugs or alcohol or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures
  10. Had donated blood within 3 months of the date of the first dose of randomized study medication, or was planning to donate blood during the study
  11. Used insulin within 3 months of Visit 1 (Screening)
  12. Had received GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of Visit 1 (Screening)
  13. Had known intolerance to metformin
  14. Had received any drug within 2 months (or five half-lives of the investigational drug, whichever was greater) of Visit 1 (Screening)
  15. Had known allergies or hypersensitivity to any component of study treatment
  16. Was employed by Elcelyx Therapeutics, Inc. (that is an employee, temporary contract worker, or designee of the company)
  17. Smoked more than 10 cigarettes per day, 3 cigars per day, 3 pipes per day, used more than 1 can of smokeless tobacco per week, or used a combination of tobacco products that approximate nicotine doses equivalent to 10 cigarettes per day
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    500 mg Met DR BID

    Two doses of 500 mg metformin delayed-release

    Drug: Met DR

  • Experimental
    1000 mg Met DR qAM

    One dose of 1000 mg metformin delayed-release in the morning

    Drug: Met DR

  • Experimental
    1000 mg Met DR qPM

    One dose of 1000 mg metformin delayed-release in the evening

    Drug: Met DR

Interventions

  • DrugMet DR

    metformin delayed-release tablets

    Also known as: EFB0027

06

What researchers measure

Primary outcomes

  1. AUC (0-24) of Plasma Metformin

    AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.

    Time frame: Times points to create the AUC (0-24) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.

  2. Cmax of Plasma Metformin

    Cmax = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.

    Time frame: Times points to determine Cmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.

  3. AUC (0-24) of Plasma Glucose

    AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.

    Time frame: Times points to create the AUC (0-24) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.75, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 18.5, 19, 19.5, 20, 21, 22, 23, and 24 hours relative to the time of the standardized dinner.

  4. Rmax (0-24) of Plasma Glucose

    Rmax (0-24) = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.

    Time frame: Times points to determine Rmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.75, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 18.5, 19, 19.5, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.

07

Results

Posted Apr 7, 2016

Participant flow

Participant flow — Overall Study
MilestoneSequence 1: ABCSequence 2: BCASequence 3: CAB
Started989
Completed treatment a968
Completed treatment b888
Completed treatment c779
Completed668
Not completed321
Withdrew: Adverse event110
Withdrew: Lost to follow-up100
Withdrew: Non-compliance110
Withdrew: Personal reason001

Outcome measures

PrimaryAUC (0-24) of Plasma Metformin

AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.

Time frame:
Times points to create the AUC (0-24) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.
Reported as:
Least squares mean · ng*h/mL
AUC (0-24) of Plasma Metformin
ng*h/mL500 mg Met DR BID1000 mg Met DR qAM1000 mg Met DR qPM
AUC (0-24) of Plasma Metformin7771 ± 6195559 ± 4337757 ± 604
Statistical analysis
  • 1000 mg Met DR qAM vs 1000 mg Met DR qPM · ANOVA · p = 0.0018 · % ratio of ls means: 71.7 · 90% CI 61.14 to 84.01Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 500 mg Met DR BID vs 1000 mg Met DR qAM · ANOVA · p = 0.0020 · % ratio of ls means: 71.5 · 90% CI 60.85 to 84.09Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 500 mg Met DR BID vs 1000 mg Met DR qPM · ANOVA · p = 0.9844 · % ratio of ls means: 99.8 · 90% CI 84.91 to 117.33Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
PrimaryCmax of Plasma Metformin

Cmax = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.

Time frame:
Times points to determine Cmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.
Reported as:
Least squares mean · ng/mL
Cmax of Plasma Metformin
ng/mL500 mg Met DR BID1000 mg Met DR qAM1000 mg Met DR qPM
Cmax of Plasma Metformin780 ± 71.7868 ± 79.81035 ± 95.2
Statistical analysis
  • 1000 mg Met DR qAM vs 1000 mg Met DR qPM · ANOVA · p = 0.1595 · % ratio of ls means: 83.8 · 90% CI 68.10 to 103.23Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 500 mg Met DR BID vs 1000 mg Met DR qAM · ANOVA · p = 0.3867 · % ratio of ls means: 111.3 · 90% CI 90.37 to 136.99Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
  • 500 mg Met DR BID vs 1000 mg Met DR qPM · ANOVA · p = 0.0294 · % ratio of ls means: 132.7 · 90% CI 107.78 to 163.39Included treatment, sequence, and period and as fixed effects and subject nested within sequence as a random effect.
PrimaryAUC (0-24) of Plasma Glucose

AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.

Time frame:
Times points to create the AUC (0-24) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.75, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 18.5, 19, 19.5, 20, 21, 22, 23, and 24 hours relative to the time of the standardized dinner.
Reported as:
Least squares mean · mg*h/dL
AUC (0-24) of Plasma Glucose
mg*h/dL500 mg Met DR BID1000 mg Met DR qAM1000 mg Met DR qPM
Pre-Treatment4668 ± 5814947 ± 6154961 ± 617
On-Treatment4438 ± 5524503 ± 5604509 ± 561
Statistical analysis
  • 1000 mg Met DR qAM · ANOVA · p = 0.0028 · % ratio of ls means: 91.0 · 95% CI 85.70 to 96.67Treatment, sequence, period, status (on-/pre-treatment) and treatment\*status as fixed effects and subject nested within sequence as a random effect.
  • 1000 mg Met DR qPM · ANOVA · p = 0.0024 · % ratio of ls means: 90.9 · 95% CI 85.58 to 96.53Treatment, sequence, period, status (on-/pre-treatment) and treatment\*status as fixed effects and subject nested within sequence as a random effect.
  • 500 mg Met DR BID · ANOVA · p = 0.0992 · % ratio of ls means: 95.1 · 95% CI 89.54 to 100.99Treatment, sequence, period, status (on-/pre-treatment) and treatment\*status as fixed effects and subject nested within sequence as a random effect.
PrimaryRmax (0-24) of Plasma Glucose

Rmax (0-24) = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.

Time frame:
Times points to determine Rmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.75, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 18.5, 19, 19.5, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.
Reported as:
Least squares mean · mg/dL
Rmax (0-24) of Plasma Glucose
mg/dL500 mg Met DR BID1000 mg Met DR qAM1000 mg Met DR qPM
Pre-Treatment279 ± 29.9290 ± 31.1302 ± 32.4
On-Treatment263 ± 28.2262 ± 28.1273 ± 29.4
Statistical analysis
  • 1000 mg Met DR qAM · ANOVA · p = 0.0006 · % ratio of ls means: 90.4 · 95% CI 85.55 to 95.56Treatment, sequence, period, status (on-/pre-treatment) and treatment\*status as fixed effects and subject nested within sequence as a random effect.
  • 1000 mg Met DR qPM · ANOVA · p = 0.0007 · % ratio of ls means: 90.5 · 95% CI 85.65 to 95.67Treatment, sequence, period, status (on-/pre-treatment) and treatment\*status as fixed effects and subject nested within sequence as a random effect.
  • 500 mg Met DR BID · ANOVA · p = 0.0389 · % ratio of ls means: 94.3 · 95% CI 89.24 to 99.69Treatment, sequence, period, status (on-/pre-treatment) and treatment\*status as fixed effects and subject nested within sequence as a random effect.

Adverse events

Collected over Approximately 36 to 91 days depending on the number of days between the start of Visit 1 and Visit 2 and the number of washout days between the treatment periods.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1000 mg Met DR qAM—0/23 (0%)6/23 (26.1%)
1000 mg Met DR qPM—0/24 (0%)5/24 (20.8%)
500 mg Met DR BID—0/23 (0%)7/23 (30.4%)
Most frequent other events
Showing 10 of 28
Most frequent other events
Event1000 mg Met DR qAM1000 mg Met DR qPM500 mg Met DR BID
DiarrhoeaGastrointestinal disorders2/230/241/23
NauseaGastrointestinal disorders0/230/242/23
VomitingGastrointestinal disorders0/230/242/23
Vessel Puncture Site PainGeneral disorders1/230/242/23
PalpitationsCardiac disorders0/230/241/23
Abdominal PainGastrointestinal disorders0/230/241/23
Breath OdourGastrointestinal disorders1/230/241/23
Dry MouthGastrointestinal disorders0/230/241/23
FatigueGeneral disorders0/231/241/23
Vessel Puncture Site SwellingGeneral disorders0/230/241/23

Baseline characteristics

Randomized (ITT) Population

Age, Continuous
Age, Continuous(years)Sequence 1: ABCSequence 2: BCASequence 3: CABTotal
Mean51.2 ± 11.7351.9 ± 13.4749.7 ± 8.4950.9 ± 10.90
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: ABCSequence 2: BCASequence 3: CABTotal
Female66416
Male32510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1: ABCSequence 2: BCASequence 3: CABTotal
Hispanic or Latino76518
Not Hispanic or Latino2248
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1: ABCSequence 2: BCASequence 3: CABTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1012
White88824
More than one race0000
Unknown or Not Reported0000
BMI
BMI(kg/m^2)Sequence 1: ABCSequence 2: BCASequence 3: CABTotal
Mean32.3 ± 3.7331.6 ± 3.9330.7 ± 1.5831.5 ± 3.17
Diabetes Management
Diabetes Management(participants)Sequence 1: ABCSequence 2: BCASequence 3: CABTotal
Diet and Exercise Only1427
Metformin Alone73717
Metformin and DPP-4 Inhibitors1102
Fasting Serum Glucose
Fasting Serum Glucose(mg/dL)Sequence 1: ABCSequence 2: BCASequence 3: CABTotal
Mean161.2 ± 29.94177.6 ± 84.17165.0 ± 54.02167.6 ± 57.04
HbA1c
HbA1c(%)Sequence 1: ABCSequence 2: BCASequence 3: CABTotal
Mean7.34 ± 1.0387.13 ± 1.1077.36 ± 1.0227.28 ± 1.017
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2016 Feb;39(2):198-205. doi: 10.2337/dc15-0488. Epub 2015 Aug 18. PubMed 26285584 ↗
  • DeFronzo RA, Buse JB, Kim T, Burns C, Skare S, Baron A, Fineman M. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia. 2016 Aug;59(8):1645-54. doi: 10.1007/s00125-016-3992-6. Epub 2016 May 23. PubMed 27216492 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 3 years after primary completion. A results delay was requested in Aug 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2013
First posted
Mar 5, 2013
Start
Dec 2012
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Results delay requested
Aug 20, 2014
Results first posted
Apr 7, 2016
Last update
Oct 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01804842
Lead sponsor
Elcelyx Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 5, 2013
Start date
Dec 2012
Primary completion
Apr 2013
Completion
Apr 2013
Results posted
Apr 7, 2016
Last update
Oct 21, 2016

Study contacts

Danielle Armas, MD
principal investigator · Celerion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion